Pharmaceuticals

Global Xerostomia Therapeutics Market Expected To Reach $6.58 Billion By 2030 With 9.1% CAGR

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Xerostomia Therapeutics Market Compare Between 2026 And 2030?

The xerostomia therapeutics market has demonstrated steady expansion in recent years. It is projected to increase from $2.24 billion in 2025 to $2.35 billion in 2026, at a compound annual growth rate (CAGR) of 5.0%. Historically, this growth can be attributed to an aging population, the widespread use of xerogenic drugs, an increasing prevalence of chronic diseases, heightened dental awareness, and hospital-based symptom management.

The xerostomia therapeutics market is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach $2.79 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. Factors contributing to this growth during the projection period include an increase in the availability of over-the-counter products, the growing incidence of side effects from cancer therapies, evolving self-medication practices, broader pharmacy network reach, and an elevated emphasis on treatments improving quality of life. Key trends defining the forecast period encompass a higher occurrence of medication-related dry mouth, a surging need for over-the-counter remedies, increased acceptance of artificial saliva solutions, the proliferation of retail and mail-order pharmacies, and a stronger concentration on managing oral symptoms.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15700&type=smp

What Factors Are Contributing To The Growth Of The Xerostomia Therapeutics Market?

The increasing occurrence of chronic illnesses is anticipated to propel the expansion of the xerostomia therapeutics market moving forward. Chronic diseases are defined as long-term medical conditions that persist for many months or years, often progressing slowly and demanding ongoing management. The primary reason for their growing prevalence is sedentary lifestyles, as a lack of regular physical activity contributes to conditions such as obesity, cardiovascular problems, and diabetes. Xerostomia therapeutics play a supportive role in managing chronic diseases by alleviating dry mouth symptoms, which in turn improves oral health, nutrition, and adherence to medication, all crucial elements in handling long-term conditions. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, showing an 18% increase from 3,065,825 cases in 2022. Consequently, the rising prevalence of chronic diseases is a significant driver for the growth of the xerostomia therapeutics market.

How Is The Xerostomia Therapeutics Market Categorized Across Its Segment Groups?

The xerostomia therapeutics market covered in this report is segmented –

1) By Type: Artificial Saliva Or Saliva Substitutes, Salivary Stimulants

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Hypermarkets And Supermarkets

3) By End-User: Adult, Pediatric

Subsegments:

1) By Artificial Saliva Or Saliva Substitutes: Oral Sprays, Gels, Lozenges, Mouthwashes

2) By Salivary Stimulants: Prescription Drugs, Over-The-Counter (Otc) Products, Chewing Gums And Lozenges

What Trends Are Shaping The Future Of The Xerostomia Therapeutics Market?

Leading companies in the xerostomia therapeutics market are prioritizing patient-friendly, non-invasive solutions, such as oral sprays, which deliver precise topical lubrication and form a protective barrier across the mouth to alleviate dry-mouth symptoms and support overall oral health. These oral sprays for xerostomia are formulations applied as a fine mist directly onto the oral mucosa (tongue, palate, inner cheeks), either creating a hydrating film or a lipid-based coating to reduce moisture evaporation, improve lubrication during chewing, swallowing, and speaking, and offer more prolonged relief for individuals prone to dry mouth. For example, in July 2023, K Pharmaceuticals, a US-based pharmaceutical company, introduced Aquoral, a clinically-proven oral spray designed for xerostomia management that employs patented Oxidized Glycerol Triesters (OGT) lipid technology to establish a long-lasting protective barrier over the oral cavity, providing relief for up to six hours with just two quick sprays, thereby reducing the need for frequent reapplication compared to water-based treatments.

Which Firms Are Influencing Competition In The Xerostomia Therapeutics Market?

Major companies operating in the xerostomia therapeutics market are GlaxoSmithKline plc, Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Synedgen Inc., Mission Pharmacal Company, Dentaid Ltd., Sunstar Suisse S.A., Forward Science Holding Inc., OraCoat, Oralieve UK Ltd., OraPharma Inc., OraVital Inc., Saliwell Limited, Bayer AG, 3M Company, Church & Dwight Co. Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Teva Pharmaceutical Industries Ltd.

Get The Full Xerostomia Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Which Region Accounts For The Largest Portion Of The Xerostomia Therapeutics Market?

North America was the largest region in the xerostomia therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xerostomia therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Xerostomia Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Xerostomia Therapeutics Market 2026, By The Business Research Company

Xerostomia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/xerostomia-therapeutics-global-market-report

Leukemia Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Mantle Cell Lymphoma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/mantle-cell-lymphoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795